Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNT1 | O60563 | 1/20 | 0.36 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.36 |
| ▸ | CDK2 | P24941 | 1/20 | 0.36 |
| ▸ | CDK9 | P50750 | 1/20 | 0.36 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.36 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.36 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.36 |
| ▸ | APLNR | P35414 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | TEK | Q02763 | 2/20 | 0.35 |
| ▸ | AURKB | Q96GD4 | 4/20 | 0.33 |
| ▸ | AURKA | O14965 | 3/20 | 0.33 |
| ▸ | TPX2 | Q9ULW0 | 3/20 | 0.33 |
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL972301 | 0.86 | TEK (0.38) | CCNT1CCNA2CDK2CDK9CCNA1 | |
| SCHEMBL971925 | 0.81 | CCNT1 (0.39) | CCNT1CCNA2CDK2CDK9CCNA1 | |
| SCHEMBL972302 | 0.81 | LMNA (0.43) | CCNT1CCNA2CDK2CDK9CCNA1 | |
| SCHEMBL581233 | 0.78 | AURKB (0.41) | CCNT1CCNA2CDK2CDK9CCNA1 | |
| SCHEMBL29891225 | 0.75 | TUBB4A (0.44) | CCNT1CCNA2CDK2CDK9CCNA1 | |
| SCHEMBL972134 | 0.68 | TEK (0.42) | TEKAURKBAURKAPDE10A | |
| SCHEMBL4482372 | 0.66 | CYP11B1 (0.51) | APLNRLMNA | |
| SCHEMBL3576830 | 0.66 | LMNA (0.50) | CCNT1CCNA2CDK2CDK9CCNA1 | |
| SCHEMBL4668256 | 0.66 | AURKA (0.38) | TEKAURKBAURKATPX2PDE10A | |
| SCHEMBL21908973 | 0.65 | LMNA (0.36) | CCNT1CCNA2CDK2CDK9CCNA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7868177-B2 | Multi-cyclic compounds and method of use | AMGEN INC. (US) | 2011-01-11 | — | — | US | disclosed |
| EP-1994030-B1 | MULTI-CYCLIC COMPOUNDS AND METHOD OF USE | AMGEN INC (US) | 2010-08-25 | — | — | EP | disclosed |
| EP-1994030-A1 | MULTI-CYCLIC COMPOUNDS AND METHOD OF USE | Amgen Inc. (US) | 2008-11-26 | — | — | EP | disclosed |
| US-20070213325-A1 | Multi-cyclic compound and method of use | AMGEN INC. (US) | 2007-09-13 | — | — | US | disclosed |
| WO-2007100646-A1 | MULTI-CYCLIC COMPOUNDS AND METHOD OF USE | AMGEN INC. (US) | 2007-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213325-A1 | Multi-cyclic compound and method of use | TIE1, CDK1, CCNB1 | CCNT1 48/4885CCNA2 19/4885CDK2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.